{
  "report_rows": [
    {
      "kpi": "Q4 adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$3.71 vs. cons $3.66",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q4 recurring revenue",
      "prediction": "BEAT",
      "answer": "pred ~$1.50B vs. cons $1.48B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q4 closed sales",
      "prediction": "MISS",
      "answer": "pred ~$118M vs. cons $122M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY27 recurring-revenue growth, constant currency",
      "prediction": "LOWER",
      "answer": "guide ~6.0% midpoint vs. cons 6.8% (FY27)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY27 adjusted EPS growth",
      "prediction": "LOWER",
      "answer": "guide ~10.0% midpoint vs. cons 10.7% (FY27)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY27 closed sales",
      "prediction": "LOWER",
      "answer": "guide ~$300M midpoint vs. cons $310M (FY27)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -2.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -4.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A modest Q4 EPS/revenue beat (~$3.71 vs. $3.66 EPS; ~$1.50B vs. $1.48B recurring revenue) is likely outweighed by lower FY27 guide midpoints (~6.0% vs. 6.8% recurring growth and ~10.0% vs. 10.7% EPS growth), plus soft closed-sales evidence (~$118M vs. $122M) that pulls out-period estimates lower.",
  "day5_confidence": "MEDIUM"
}